PUBLIC COMPANY
saveIPSEN
USupdated 2mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- —Odevixibat Outcomes in Patients With PFIC Versus an External Control Cohort (OvEC-PFIC)
- phase3A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC)
- phase3A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
- —A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment
- phase2A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.
- phase2A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
- —Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment
- phase3A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
🐶 Hiring Signal
News
- PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approvalA former congressman will take over for prominent lobbyist Steve Ubl. Elsewhere, recent buyout deals paid dividends for Mirum and AbbVie.biopharma_dive · 1d ago
- FDA nod for Mirum’s Atebrioz makes 3 options for ultra-rare bone diseaseThe approval of Mirum Pharmaceuticals’ ALK2 inhibitor for fibrodysplasia ossificans progressiva on Friday adds a third option for patients who had long been without any treatments, joining Regenero…biospace · 3d ago
- 9 pharma leaders sound ‘alarm bells’ on biotech’s decline in EuropeFrustrated by a slump that’s seen Europe lose ground to the U.S. and China, several top drugmakers are calling for speedier clinical trials, intellectual property protections and “fiscal flexibility.”biopharma_dive · 8d ago
- STAT+: Pharmalittle: We’re reading about Novo plans to expand its pipeline, early Alkermes ADHD data, and moreNovo Nodisk outlined plans to expand its pipeline and find new products that it could sell more like consumer goods than traditional medicinesstat · 10d ago
- Roche inks $1.53B deal for Simcere’s B-cell-targeting antibodyRoche is paying oncology-focused Simcere Zaiming $75 million upfront for global rights to a preclinical trispecific antibody targeting B-cell-mediated diseases.fiercebiotech · 1mo ago
- Regeneron to challenge Ipsen as FDA clears bone disease drugPasatru’s approval sets up a market battle in a rare indication where the only available treatment has generated disappointing sales.biopharma_dive · 1mo ago
- Regeneron wins FDA approval to challenge Ipsen for rare bone disease marketRegeneron’s Pasatru is the second fibrodysplasia ossificans progressiva drug approved in the U.S., following the 2023 approval of Ipsen’s Sohonos.biospace · 1mo ago
- Slate, Fulcrum to combine in reverse mergerFulcrum announced in June it would seek strategic alternatives after U.S. regulators expressed concern over the viability of its sickle cell drug.biopharma_dive · 1mo ago
- ‘We’re not afraid of competition’: BioCryst CEO sets out strategy after scrapping internal discoveryBioCryst CEO Charlie Gayer told Fierce the company is “not getting away from science and R&D” despite shutting down its internal discovery efforts.fiercebiotech · 1mo ago
- Ipsen has 'firepower' for more deals with €2B war chestIpsen has its eyes trained on more M&A — and has €2 billion worth of “firepower” to do it, based on its cash position at the end of June, CFO Aymeric Le Chatelier said. “If we ...endpoints · 2mo ago
comments(0)
5-min edit window · permanent after that